PCM1

Across TCGA pan-cancer cohorts, PCM1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PCM1 data layer compared with 25 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PCM1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PCM1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

PDAC, LUAD, and HNSC are the cancer types where PCM1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	IV	0.245	0.766	.017	9	view →
LUAD	OS	Median	III,IV	1.000	0.770	.007	6	view →
HNSC	OS	Tertile	III,IV	0.758	0.551	.032	2	view →
LSCC	OS	Quartile	III,IV	0.877	0.563	.049	2	view →
CCRCC	OS	Median	All	0.741	1.000	.027	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PCM1–PDAC (DFS)

Open the PDAC breakdown →